4F

Delta Demonstrates Smart EV Charging Station for Sustainable Cities at 2035 E-Mobility Taiwan

Retrieved on: 
Thursday, April 13, 2023
EV, Intergovernmental Panel on Climate Change, Exhibition, Electronics, Climate change, AC, Golf, Belgrade Fair – Hall 1, 4F, EVS, HVAC, EV100, LED, IPCC, Hall, Taipei Nangang Exhibition Center metro station, Vehicle registration plates of Nepal, City, Growth, BMS, ADAS, AD, Integration, CO2, Electric battery, Online shopping, Delta

TAIPEI, April 13, 2023 /PRNewswire/ -- Delta, a global leading provider of power and thermal management solutions, today unveiled its Smart EV Charging Station theme concept at 2035 E-Mobility Taiwan to demonstrate how its innovative energy-saving products and solutions, which include EV powertrain and power management systems, microgrid-supported EV charging infrastructure, and powertrains for e-scooters and e-bikes, are enabling smart e-mobility for sustainable cities.

Key Points: 
  • TAIPEI, April 13, 2023 /PRNewswire/ -- Delta, a global leading provider of power and thermal management solutions, today unveiled its Smart EV Charging Station theme concept at 2035 E-Mobility Taiwan to demonstrate how its innovative energy-saving products and solutions, which include EV powertrain and power management systems, microgrid-supported EV charging infrastructure, and powertrains for e-scooters and e-bikes, are enabling smart e-mobility for sustainable cities.
  • Shan Shan Guo, Delta's Chief Brand Officer, said, "We are delighted that 2035 E-Mobility Taiwan returns in full force after the pandemic lockdown.
  • Our 'Delta Charging Hub' theme integrates Delta's brand-new corporate identity elements as we bring to life a smart, eco-friendly and convenient EV charging experience to our customers.
  • Moreover, our microgrid-supported EV charging infrastructure, which can generate, store, save and, deploy electricity, is a testament to our commitment to nurturing smart cities for generations to come."

eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 7, 2022
Private Securities Litigation Reform Act, RNA transfection, Research and development, University of California, San Francisco, Infection, DARPA, University, D&O, Effector, Protein, U.S. Securities and Exchange Commission, COVID-19, IPO, Cyclin D1, Case Western Reserve University, Survival, Cyclic permutation, G&A, MNK, Pfizer, Genentech, PD-L1, 4F, San Francisco, GLOBE, NASDAQ, KRAS, Fulvestrant, Mayank Gandhi, Clinical trial, Administration, Research, Net operating loss, Therapy, R, Safety, Pembrolizumab, STRI, Patient, Expense, Cancer, CBO, Citigroup, Breast cancer, CMO, ER, Investment, Escape Room, Stri Parva, HIV disease progression rates, Security (finance), Medical imaging, Pharmaceutical industry, Management, Vaccine, Income, KICKSTART, NSCLC

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses were $6.6 million for the quarter ended September 30, 2022, compared to $5.0 million for the same quarter of 2021.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.5 million for the quarter ended September 30, 2022, compared to $4.1 million for the same quarter of 2021.
  • Other Income (Expense): Other expense was $0.3 million for the quarter ended September 30, 2022 and other income for the quarter ended September 30, 2021 was $17.6 million.
  • Other expense in the quarter ended September 30, 2022 consisted primarily of interest expense associated with the companys term loan.

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, October 31, 2022
Escape Room, RNA transfection, EIF4E, Therapy, Survival, Stri, MNK, Pfizer, Pembrolizumab, KRAS, Cancer, 4F, GLOBE, STRI, COVID-19, University of California, San Francisco, ER, University, NASDAQ, Investor, Protein, Patient, San Francisco, SAN, DARPA, NSCLC, EIF4A, Pharmaceutical industry, KICKSTART

A replay of the webcasts will be available for 30 days following the event.

Key Points: 
  • A replay of the webcasts will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

Retrieved on: 
Wednesday, October 26, 2022
Genome, Stri Parva, Survival, University, Virus, Clinical trial, Security (finance), University of California, San Francisco, U.S. Securities and Exchange Commission, STRI, NASDAQ, Private Securities Litigation Reform Act, Safety, Cancer, Prevalence, Vaccine, CDK, EIF4E, 4F, Receptor tyrosine kinase, Pembrolizumab, COVID-19, KRAS, RNA, Patient, QBI, Effector, Protein, Disease, Orthornavirae, Research, NSCLC, GLOBE, EIF4A, University of California, ER, Therapy, UC, RNA transfection, SAN, UC San Diego Health, Membrane protein, UCSF, Biology, Escape Room, Severe acute respiratory syndrome coronavirus 2, MNK, DARPA, Pfizer, Solution, Pharmaceutical industry, KICKSTART, Nature, Pharmacy

eFFECTOR anticipates opening enrollment in the third cohort by the end of 2022, and expects to report topline data for all three cohorts in the first half of 2023.

Key Points: 
  • eFFECTOR anticipates opening enrollment in the third cohort by the end of 2022, and expects to report topline data for all three cohorts in the first half of 2023.
  • Zotatifin is an investigational host-directed antiviral, meaning that it acts on a human protein that the SARS-CoV-2 virus hijacks to synthesize new viruses.
  • As such, zotatifin may have a higher barrier to viral mutational escape than therapies that target components of the virus itself.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

Retrieved on: 
Monday, September 26, 2022
University, EIF4E, Therapy, Stri Parva, COVID-19, University of California, San Francisco, Effector, RNA transfection, EIF4A, NSCLC, Acquisition, DARPA, Private Securities Litigation Reform Act, Partnership, STRI, VC, ER, U.S. Securities and Exchange Commission, Cancer, Survival, Patient, Clinical trial, IPO, Atezolizumab, Protein, San Francisco, NASDAQ, Negotiation, SAN, KRAS, Akira Toriyama's Manga Theater, MNK, Research, GLOBE, Security (finance), Case Western Reserve University, Genentech, Pembrolizumab, Escape Room, Citigroup, 4F, Pfizer, Pharmaceutical industry, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.
  • Mayank is an accomplished leader with extensive experience in the biopharmaceutical industry including corporate development, partnering, product development and commercialization, said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.
  • Mayank will be instrumental in maximizing the value of tomivosertib and zotatifin as both compounds advance in clinical development.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

Retrieved on: 
Wednesday, September 21, 2022
EIF4E, Stri, COVID-19, University of California, San Francisco, Effector, RNA transfection, EIF4A, NSCLC, DARPA, 4F, Survival, STRI, Patient, ER, Cancer, Protein, San Francisco, KRAS, Escape Room, Pembrolizumab, University, MNK, Pfizer, Pharmaceutical industry, Vaccine, KICKSTART

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.

Key Points: 
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • Zotatifin, eFFECTORs inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

Retrieved on: 
Wednesday, September 14, 2022
Hospital, Receptor tyrosine kinase, Plasma, EIF4E, Safety, Stri Parva, COVID-19, UCSF School of Pharmacy, University of California, San Francisco, Effector, RNA transfection, Orthornavirae, Virus, NSCLC, EIF4A, QBI, Severe acute respiratory syndrome coronavirus 2, DARPA, Review, Private Securities Litigation Reform Act, Therapy, COVID, U.S. Securities and Exchange Commission, STRI, Government, ER, Patient, Test, University of California, Cancer, Survival, Disease, Clinical trial, UCSF School of Medicine, Protein, Biology, Solution, NASDAQ, SAN, KRAS, RNA, MNK, Research, Security (finance), GLOBE, Escape Room, Pembrolizumab, University, Genome, CDK, 4F, Pfizer, Death, Pharmaceutical industry, Vaccine, Pharmacy, KICKSTART, Nature

SAN DIEGO and REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has dosed the first patient in the second cohort of its Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection. The study is a double-blind, randomized, placebo-controlled trial evaluating the safety and antiviral activity of a single dose of zotatifin and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco, under a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency.

Key Points: 
  • Dose escalation to the second cohort comes after the positive recommendation of the independent data safety monitoring board upon review of safety data from the first dose cohort.
  • The completed cohort also included the first subjects dosed with a sub-cutaneous formulation of zotatifin and preliminary analysis demonstrated equivalent plasma drug levels compared to IV delivery.
  • Achieving equivalent drug levels when zotatifin was delivered by the sub-cutaneous route provides an opportunity for convenient dosing in both the COVID and cancer settings.
  • As such, zotatifin may have a higher barrier to viral mutational escape than therapies that target components of the virus itself.

eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
University, COVID-19, San Francisco, Cancer, Survival, STRI, Pfizer, Protein, Stri, DARPA, University of California, San Francisco, EIF4E, 4F, Pembrolizumab, KRAS, NSCLC, ER, Investor, Webcast, RNA transfection, MNK, EIF4A, Patient, Escape Room, Online shopping, Pharmaceutical industry, KICKSTART

A replay of the webcast will be available for 30 days following the event.

Key Points: 
  • A replay of the webcast will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, Stri Parva, 4F, DARPA, Survival, UCLA Anderson School of Management, GLOBE, Duke University School of Medicine, EIF4E, University, Private Securities Litigation Reform Act, Warner, Cancer, Clinical trial, The Lancet, Security (finance), Research, Pfizer, EIF4A, STRI, NSCLC, Patient, Pembrolizumab, Therapy, CMO, COVID-19, Large-cell lung carcinoma, SAN, Effector, Amgen, NASDAQ, San Francisco, KRAS, MNK, University of California, San Francisco Fetal Treatment Center, ER, Protein, Journal, Escape Room, RNA transfection, American Journal of Clinical Oncology, Pharmaceutical industry, KICKSTART, Lancet

SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer.
  • He will also be responsible for developing registration strategies for both programs and exploring expansion into additional oncology indications.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

Retrieved on: 
Tuesday, June 7, 2022
Company, Conference, ER, Survival, JMP, University of California, San Francisco, DARPA, EIF4A, ET, MNK, 4F, Pfizer, Investor, University, Pembrolizumab, STRI, Therapy, GLOBE, Patient, RNA transfection, San Francisco, COVID-19, NASDAQ, SAN, Escape Room, EIF4E, NSCLC, KRAS, Stri, Cancer, Protein, Pharmaceutical industry, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference.
  • The eFFECTOR Team is scheduled to hold a fireside chat on June 15th at 10:30 am ET and will host investor meeting at the conference through June 16th.
  • A live webcast will be available on the "Events and Presentation" page of the Investors section of the Companys website.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.